Home>>Signaling Pathways>> Alzheimer>> Neuroscience>>COG 133
COG 133 目录号 GP10010

ApoE mimetic peptide

规格 价格 库存 购买数量
1mg
¥483.00
现货
5mg
¥1,565.00
现货
10mg
¥2,678.00
现货
25mg
¥3,654.00
现货

Customer Review

Based on customer reviews.

电话:400-920-5774 Email: sales@glpbio.cn

Sample solution is provided at 25 µL, 10mM.

质量管理

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment [1]:

Cell lines

IEC-6 cell monolayers

Preparation method

Soluble to 1 mg/ml in sterile water. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0.02, 0.2, 2, 5, 10, and 20 μM, 24 h

Applications

COG 133 (0.02, 0.2, and 2.0 μM) improved cell numbers in glutamine free media. In IEC-6 cells, COG 133 (0.2-20 μM) improved cell migration following 5-FU challenge, reaching the same migration level as controls.

Animal experiment [1]:

Animal models

5-fluorouracil (5-FU)-challenged Swiss mice, C57BL6J ApoE knock-out mice

Dosage form

Intraperitoneal injection, 0.3, 1, and 3 μM, twice daily for 4 days

Application

COG 133 (3 μM) significantly increased the mitotic crypt numbers in C57BL6J wild-type animals. COG 133 treatment improved crypt architecture and reduced lamina propria inflammation. COG 133 (3 μM) significantly reduced the intestinal MPO levels. COG 133 partially decreased TNF-α level in the proximal small intestine from 5-FU-treated mice. In both wild-type and ApoE knock-out mice, COG 133 (3 μM) reverted the increase in Tunel-positive cells in the proximal intestine induced by 5-FU. COG 133 caused higher expression of the NF-κB in the improved intestinal mucosa.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Azevedo O G R, Oliveira R A C, Oliveira B C, et al. Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis[J]. BMC gastroenterology, 2012, 12(1): 35.

Chemical Properties

Cas No. 514200-66-9 SDF
别名 Leu-Arg-Val-Arg-Leu-Ala-Ser-His-Leu-Arg-Lys-Leu-Arg-Lys-Arg-Leu-Leu
化学名 N/A
Canonical SMILES N/A
分子式 C97H181N37O19 分子量 2169.73
溶解度 ≥ 217mg/mL in DMSO 储存条件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • 摩尔浓度计算器

  • 稀释计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

产品描述

COG 133, (C97H181N37O19), a peptide with the sequence Ac-Leu-Arg-Val-Arg-Leu-Ala-Ser-His-Leu-Arg-Lys-Leu-Arg-Lys-Arg-Leu-Leu-amide,MW= 2169.73.Apolipoprotein E (ApoE) is 299 amino acids long and transports lipoproteins1, fat-soluble vitamins, and cholesterol into the lymph system and then into the blood. It is synthesized principally in the liver, but has also been found in other tissues such as the brain, kidneys, and spleen. In the nervous system, non-neuronal cell types, most notably astroglia and microglia, are the primary producers of APOE, while neurons preferentially express the receptors for APOE. There are seven currently identified mammalian receptors for APOE which belong to the evolutionarily conserved low density lipoprotein receptor gene family.APOE was initially recognized for its importance in lipoprotein metabolism and cardiovascular disease2. Defects in APOE result in familial dysbetalipoproteinemia aka type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron, VLDL and LDL remnants[citation needed]. More recently, it has been studied for its role in several biological processes not directly related to lipoprotein transport, including Alzheimer's disease (AD), immunoregulation, and cognition3.

References:
1. Singh PP, Singh M, Mastana SS (2002). "Genetic variation of apolipoproteins in North Indians". Hum. Biol. 74 (5): 673-82.
2. van den Elzen P, Garg S, LeȮn L, Brigl M, Leadbetter EA, Gumperz JE, Dascher CC, Cheng TY, Sacks FM, Illarionov PA, Besra GS, Kent SC, Moody DB, BrennerMB. (2005). "Apolipoprotein-mediated pathways of lipid antigen presentation.". Nature 437 (7060): 906-10.
3. Zhang HL, Wu J, Zhu J (2010). "The Role of Apolipoprotein E in Guillain-BarrȦ Syndrome and Experimental Autoimmune Neuritis". J. Biomed. Biotechnol. 2010: 357412.